Welcome to our dedicated page for Novocure SEC filings (Ticker: NVCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scanning Novocure’s latest 300-page disclosures for clinical-trial milestones or reimbursement updates can feel overwhelming. Oncology device filings must track FDA feedback, global patient enrollments, and complex royalty agreements—details buried deep inside a single annual report 10-K. If you came here after searching "Novocure SEC filings explained simply" or "How do I track Novocure insider trading Form 4 transactions?", you’re in the right place.
Stock Titan’s platform turns each dense document into plain-language insight. Our AI produces side-by-side summaries so you can move from Novocure quarterly earnings report 10-Q filing headlines to full cash-flow tables in one click. Real-time alerts surface Novocure Form 4 insider transactions real-time, letting you monitor executive sentiment before data readouts. Need a quick brief? Try "understanding Novocure SEC documents with AI"—our engine highlights segment revenue shifts, TTFields adoption metrics, and litigation updates without the jargon.
Whether you’re analyzing a sudden Novocure 8-K material events explained notice, comparing option grants inside the Novocure proxy statement executive compensation, or scanning Novocure executive stock transactions Form 4, every filing is indexed, searchable, and updated the moment it hits EDGAR. Practical use cases include:
- Flagging device-sales momentum through Novocure earnings report filing analysis
- Spotting insider buying patterns ahead of pivotal trial updates
- Cross-checking R&D spend trends with previous periods
No more piecing together spreadsheets or waiting for secondary sources; our AI delivers a Novocure annual report 10-K simplified experience built for portfolio managers, sell-side analysts, and diligent retail investors alike.
Capital World Investors (CWI) reports beneficial ownership of 6,382,848 shares of NovoCure Ltd. common stock, representing 5.7% of the 111,485,634 shares believed outstanding. CWI is identified as an investment adviser division of Capital Research and Management Company and related entities that provide investment management services under the name "Capital World Investors." The filing states CWI has sole voting and sole dispositive power over all 6,382,848 shares and that the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Schedule 13G/A amendment highlights: Capital International Investors (CII) reports beneficial ownership of 0 shares of NovoCure Ltd. (NVCR) common stock as of the event date 06/30/2025. This represents 0.0 % of the issuer’s 111,485,634 outstanding shares. All voting and dispositive powers—sole or shared—are now listed as zero.
The filing classifies CII as an investment adviser (IA) under Rule 13d-1(b). The certification confirms the shares were held in the ordinary course of business and not for the purpose of influencing control. CII’s exit moves its ownership below the 5 % reporting threshold and effectively eliminates a prior institutional position in NovoCure.
Investor takeaway: A complete liquidation by a large asset manager can signal changing sentiment and may increase free float, potentially adding near-term supply to the market and reducing perceived institutional sponsorship. However, no other financial metrics or strategic updates for NovoCure are provided in this document.
FAQ
What is the current stock price of Novocure (NVCR)?
What is the market cap of Novocure (NVCR)?
